Clinical Trials
10 results for Bladder Cancer
Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy
- Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
- Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
- Study ID: NCT01050504
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney
- Condition: Urothelial Cancer, Cancer, Bladder Neoplasms, Urinary Bladder Cancer
- Study ID: NCT00872495
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
- Condition: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
- Intervention: Drug: Gemcitabine Hydrochloride, Drug: Cisplatin, Biological: Pegfilgrastim, Procedure: Conventional Surgery, Procedure: Radical Cystectomy, Other: Chemoradiotherapy
- Study ID: NCT03609216
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
- Condition: Bladder Cancer
- Intervention: Drug: Abemaciclib
- Study ID: NCT03837821
An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
- Condition: Urothelial Cancer
- Intervention: Drug: Enfortumab vedotin, Drug: Pembrolizumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Gemcitabine
- Study ID: NCT04223856
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
- Condition: Renal Pelvis and Ureter Urothelial Carcinoma
- Study ID: NCT04628767
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)
- Condition: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
- Study ID: NCT05544552
An Open-Label, Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations
- Condition: Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
- Study ID: NCT05614739
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours (TROPION-PanTumor03)
- Condition: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer
- Study ID: NCT05489211
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors
- Condition: Advanced Solid Tumors
- Study ID: NCT05941507